Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 33

1.

Hyperpolarization-activated cyclic nucleotide-gated 2 (HCN2) ion channels drive pain in mouse models of diabetic neuropathy.

Tsantoulas C, Laínez S, Wong S, Mehta I, Vilar B, McNaughton PA.

Sci Transl Med. 2017 Sep 27;9(409):eaam6072. doi: 10.1126/scitranslmed.aam6072.

PMID:
28954930
2.

Thymoquinone Alleviates the Experimental Diabetic Peripheral Neuropathy by Modulation of Inflammation.

Chen L, Li B, Chen B, Shao Y, Luo Q, Shi X, Chen Y.

Sci Rep. 2016 Aug 22;6:31656. doi: 10.1038/srep31656.

3.

Comparative Proteomic Study of Fatty Acid-treated Myoblasts Reveals Role of Cox-2 in Palmitate-induced Insulin Resistance.

Chen X, Xu S, Wei S, Deng Y, Li Y, Yang F, Liu P.

Sci Rep. 2016 Feb 22;6:21454. doi: 10.1038/srep21454.

4.

Inflammation as a Therapeutic Target for Diabetic Neuropathies.

Pop-Busui R, Ang L, Holmes C, Gallagher K, Feldman EL.

Curr Diab Rep. 2016 Mar;16(3):29. doi: 10.1007/s11892-016-0727-5. Review.

5.

PGE2, Kidney Disease, and Cardiovascular Risk: Beyond Hypertension and Diabetes.

Nasrallah R, Hassouneh R, Hébert RL.

J Am Soc Nephrol. 2016 Mar;27(3):666-76. doi: 10.1681/ASN.2015050528. Epub 2015 Aug 28. Review.

6.

Antioxidant strategies in the management of diabetic neuropathy.

Oyenihi AB, Ayeleso AO, Mukwevho E, Masola B.

Biomed Res Int. 2015;2015:515042. doi: 10.1155/2015/515042. Epub 2015 Mar 2. Review.

7.

BTBR ob/ob mice as a novel diabetic neuropathy model: Neurological characterization and gene expression analyses.

O'Brien PD, Hur J, Hayes JM, Backus C, Sakowski SA, Feldman EL.

Neurobiol Dis. 2015 Jan;73:348-55. doi: 10.1016/j.nbd.2014.10.015. Epub 2014 Oct 30.

8.

Targeting inflammation in diabetes: Newer therapeutic options.

Agrawal NK, Kant S.

World J Diabetes. 2014 Oct 15;5(5):697-710. doi: 10.4239/wjd.v5.i5.697. Review.

9.

Diabetic neuropathy: mechanisms, emerging treatments, and subtypes.

Albers JW, Pop-Busui R.

Curr Neurol Neurosci Rep. 2014 Aug;14(8):473. doi: 10.1007/s11910-014-0473-5. Review.

10.

Neuroinflammation and oxidative stress in diabetic neuropathy: futuristic strategies based on these targets.

Sandireddy R, Yerra VG, Areti A, Komirishetty P, Kumar A.

Int J Endocrinol. 2014;2014:674987. doi: 10.1155/2014/674987. Epub 2014 Apr 30. Review.

11.

Gp120 in the pathogenesis of human immunodeficiency virus-associated pain.

Yuan SB, Shi Y, Chen J, Zhou X, Li G, Gelman BB, Lisinicchia JG, Carlton SM, Ferguson MR, Tan A, Sarna SK, Tang SJ.

Ann Neurol. 2014 Jun;75(6):837-50. doi: 10.1002/ana.24139. Epub 2014 May 28.

12.

Mouse models of diabetic neuropathy.

O'Brien PD, Sakowski SA, Feldman EL.

ILAR J. 2014;54(3):259-72. doi: 10.1093/ilar/ilt052. Review.

13.

12/15-Lipoxygenase inhibition counteracts MAPK phosphorylation in mouse and cell culture models of diabetic peripheral neuropathy.

Stavniichuk R, Obrosov AA, Drel VR, Nadler JL, Obrosova IG, Yorek MA.

J Diabetes Mellitus. 2013 Aug;3(3). doi: 10.4236/jdm.2013.33015.

14.

Effects of triple antioxidant therapy on measures of cardiovascular autonomic neuropathy and on myocardial blood flow in type 1 diabetes: a randomised controlled trial.

Pop-Busui R, Stevens MJ, Raffel DM, White EA, Mehta M, Plunkett CD, Brown MB, Feldman EL.

Diabetologia. 2013 Aug;56(8):1835-44. doi: 10.1007/s00125-013-2942-9. Epub 2013 Jun 6.

15.

Endoplasmic reticulum stress plays a key role in the pathogenesis of diabetic peripheral neuropathy.

Lupachyk S, Watcho P, Stavniichuk R, Shevalye H, Obrosova IG.

Diabetes. 2013 Mar;62(3):944-52. doi: 10.2337/db12-0716. Epub 2013 Jan 30.

16.

Diabetic peripheral neuropathy: should a chaperone accompany our therapeutic approach?

Farmer KL, Li C, Dobrowsky RT.

Pharmacol Rev. 2012 Oct;64(4):880-900. doi: 10.1124/pr.111.005314. Epub 2012 Aug 10. Review.

17.

What do we know and we do not know about cardiovascular autonomic neuropathy in diabetes.

Pop-Busui R.

J Cardiovasc Transl Res. 2012 Aug;5(4):463-78. doi: 10.1007/s12265-012-9367-6. Epub 2012 May 30. Review.

18.

Na+/H+-exchanger-1 inhibition counteracts diabetic cataract formation and retinal oxidative-nitrative stress and apoptosis.

Lupachyk S, Stavniichuk R, Komissarenko JI, Drel VR, Obrosov AA, El-Remessy AB, Pacher P, Obrosova IG.

Int J Mol Med. 2012 Jun;29(6):989-98. doi: 10.3892/ijmm.2012.933. Epub 2012 Mar 7.

19.

Interplay of sorbitol pathway of glucose metabolism, 12/15-lipoxygenase, and mitogen-activated protein kinases in the pathogenesis of diabetic peripheral neuropathy.

Stavniichuk R, Shevalye H, Hirooka H, Nadler JL, Obrosova IG.

Biochem Pharmacol. 2012 Apr 1;83(7):932-40. doi: 10.1016/j.bcp.2012.01.015. Epub 2012 Jan 20.

20.

Baicalein alleviates diabetic peripheral neuropathy through inhibition of oxidative-nitrosative stress and p38 MAPK activation.

Stavniichuk R, Drel VR, Shevalye H, Maksimchyk Y, Kuchmerovska TM, Nadler JL, Obrosova IG.

Exp Neurol. 2011 Jul;230(1):106-13. doi: 10.1016/j.expneurol.2011.04.002. Epub 2011 Apr 16.

Supplemental Content

Support Center